Stock listing

NASDAQ:IMMX Immix Biopharma, Inc. Stock

Home listing (NASDAQ) of Immix Biopharma, Inc.

Follow Immix Biopharma, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:IMMX

$6.96 USD -0.15 (-2.1%)

Close on Nov 20, 2026

Past year +73.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$6.90 – $7.50 USDNov 20, 2026
Volume
1.57M sharesNov 20, 2026
Market cap
$577.0M USDAt the close on Nov 20, 2026 · price × 82.90M shares outstanding
52-week range
$3.78 – $15.10 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$15.43M USDMedian day 1.29M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Immix Biopharma, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:IMMX · Home$6.96 USD-0.15 (-2.1%)1,572,782$6.99$7.50$6.90$7.11Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:IMMX · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$6.96-0.15-2.1%$6.99$7.50$6.901,572,782
$7.11-0.09-1.2%$7.235$7.43$7.05876,255
$7.20-0.28-3.7%$7.48$7.52$7.12993,758
$7.48-0.36-4.6%$7.83$8.01$7.4551,004,634
$7.84-0.23-2.9%$8.25$8.375$7.661,027,813
$8.07-0.59-6.8%$8.40$8.45$8.06954,606
$8.66+0.31+3.7%$8.40$8.72$8.301,070,704
$8.35-0.22-2.6%$8.37$8.77$8.132825,479
$8.57+0.51+6.3%$8.09$8.89$7.901,270,839
$8.06+0.86+11.9%$7.24$8.17$7.181,444,882
$7.20-0.77-9.7%$7.86$7.95$7.121,414,576
$7.97+0.26+3.4%$7.93$8.16$7.561,249,715
$7.71+0.45+6.2%$7.33$7.80$7.1681,072,329
$7.26-0.42-5.5%$7.65$7.913$7.1851,506,997
$7.68-0.30-3.8%$7.86$8.10$7.561,381,203
$7.98-0.145-1.8%$8.11$8.36$7.8351,073,785
$8.125+0.075+0.9%$7.98$8.21$7.881,229,694
$8.05-0.01-0.1%$8.00$8.16$7.8491,147,026
$8.06-0.09-1.1%$8.17$8.31$7.991,116,278
$8.15-0.20-2.4%$8.34$8.89$7.881,203,479
$8.35-0.16-1.9%$8.40$8.73$8.23817,970
$8.51-0.40-4.5%$8.94$9.10$8.471,540,507
$8.91+0.69+8.4%$8.26$9.03$8.2351,226,147
$8.22+0.24+3.0%$8.05$8.35$8.001,302,419
$7.98-0.70-8.1%$8.67$8.67$7.951,503,800
$8.68+0.17+2.0%$8.51$8.905$8.451,314,400
$8.51-0.18-2.1%$8.60$8.87$8.421,360,500
$8.69-0.56-6.1%$9.10$9.29$8.661,483,600
$9.25-0.21-2.2%$9.42$9.56$9.18936,200
$9.46+0.17+1.8%$9.29$9.53$9.181,109,000
$9.29-0.20-2.1%$9.34$9.37$8.961,289,000
$9.49-0.15-1.6%$9.50$9.69$9.401,382,100
$9.64-0.49-4.8%$10.20$10.20$9.5151,214,600
$10.13+0.45+4.6%$9.71$10.33$9.551,597,500
$9.68-0.55-5.4%$10.35$10.37$9.482,548,000
$10.23-0.175-1.7%$10.25$10.48$9.861,648,300
$10.41-0.135-1.3%$10.61$11.25$10.392,408,600
$10.54-0.93-8.1%$11.64$11.85$10.075,759,500
$11.47+0.50+4.6%$10.82$11.84$10.70995,600
$10.97-0.73-6.2%$11.78$11.99$10.821,828,200
$11.70-0.22-1.8%$11.87$11.97$11.191,535,800
$11.92-0.91-7.1%$12.80$12.84$11.711,168,200
$12.83+0.36+2.9%$12.45$12.90$12.31948,100
$12.47-0.03-0.2%$12.59$12.71$12.141,329,500
$12.50-0.22-1.7%$12.68$12.84$12.344,183,900
$12.72+0.80+6.7%$12.24$12.75$12.071,184,700
$11.92-0.22-1.8%$12.28$12.46$11.751,421,900
$12.14-0.07-0.6%$12.49$12.63$11.811,054,900
$12.21+0.07+0.6%$12.44$12.59$11.981,079,600
$12.14-0.56-4.4%$12.86$13.29$12.021,190,300
$12.70+0.39+3.2%$12.08$12.77$11.911,656,300
$12.31-0.94-7.1%$13.12$13.23$12.241,285,600
$13.25-0.66-4.7%$13.70$13.89$12.751,420,200
$13.91+0.08+0.6%$13.68$14.09$13.601,050,700
$13.83-0.13-0.9%$14.14$14.14$13.52987,200
$13.96-0.05-0.4%$14.00$14.23$13.421,578,200
$14.01-0.02-0.1%$13.86$14.26$13.621,277,400
$14.03+0.09+0.6%$13.70$14.15$13.521,326,800
$13.94-0.37-2.6%$14.06$14.17$13.761,143,400
$14.31+0.24+1.7%$14.03$14.61$13.771,511,000
$14.07-0.40-2.8%$14.45$14.55$13.801,385,000
$14.47+0.86+6.3%$13.60$15.10$13.493,651,500
$13.61-0.05-0.4%$13.66$13.80$12.901,415,400
$13.66+0.50+3.8%$13.36$13.76$13.121,510,600
$13.16-0.03-0.2%$12.98$13.20$12.691,666,200
Ticker
NASDAQ:IMMX
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Immix Biopharma, Inc. news

Immix Biopharma, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
19 in the last 12 months · 106 in all · newest Nov 12, 2026 · oldest 2021
Decks
25 decks · latest September 2026

Where Immix Biopharma, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:IMMX · Home listing · This pageNASDAQUnited StatesUSD
BOATS:IMMXBOATSUnited StatesUSD

Valuation

Price/book 1.7× against a median of 2.4×: 4th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$241.7M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
1.7×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.60

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Immix Biopharma, Inc. · NASDAQ:IMMXUS$577.0MUS$241.7Mn/an/an/a1.7×n/a0.0×1.60
Alebund Pharmaceuticals (Jiangsu) Limited Class H · HKEX:9637US$608.9MUS$483.6Mn/a106×n/a2.9×n/a0.4×n/a
Annexon, Inc. · NASDAQ:ANNXUS$587.7MUS$423.7Mn/an/an/a4.1×n/a0.3×1.63
Design Therapeutics, Inc. · NASDAQ:DSGNUS$577.6MUS$371.5Mn/an/an/a2.9×n/a0.0×1.29
Cullinan Therapeutics, Inc. · NASDAQ:CGEMUS$577.1MUS$289.6Mn/an/an/a2.0×n/a0.0×1.45
Entera Bio Ltd. · NASDAQ:ENTXUS$574.8MUS$308.9Mn/an/an/a2.1×n/a0.0×0.76
DBV Technologies SA · EURONEXT:DBVUS$571.8MUS$430.7Mn/a47.1×n/a3.9×n/a0.1×n/a
Ascletis Pharma, Inc. · HKEX:1672US$571.3MUS$232.4Mn/a765×n/a1.7×n/a0.0×n/a
4D Molecular Therapeutics, Inc. · NASDAQ:FDMTUS$565.1MUS$277.8Mn/a2.9×n/a1.7×−208.6%0.1×1.75
Bicara Therapeutics Inc. · NASDAQ:BCAXUS$560.3MUS$118.8Mn/an/an/a1.4×n/a0.0×1.37
Lepu Biopharma Co. Ltd. Class H · HKEX:2157US$554.8MUS$613.4M14.6×4.5×22.9×2.6×28.0%0.8×n/a
Median of the othersUS$573.3MUS$340.2M14.6×47.1×22.9×2.4×−90.3%0.0×1.41

Forecasts

4 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
23.80 USD · Analysts' mean
EPS, year to Dec 2026
-0.72 · 8 analysts

Team and board

Officers

OfficerRole
Ilya RachmanChief Executive and Scientific Officer
Gabriel MorrisPresident and Chief Financial Officer
David HeHead of Technical Operations
David MarksChief Medical Officer
Michael GrabowChief Commercial Officer

Board

DirectorRole
Carey NgIndependent Director
Helen AdamsIndependent Director
Jane BuchanIndependent Director
Jason HsuIndependent Director
Magda MarquetIndependent Director
Nancy ChangIndependent Director
Yekaterina ChudnovskyIndependent Director

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026 · After close−2.9%
Q2 2026Aug 7, 2026+0.7%
Q1 2026May 7, 2026 · After close+2.2%
Q4 2025Feb 25, 20260.0%
Q3 2025Nov 7, 2025 · After close+2.9%
Q2 2025Aug 8, 2025 · After close−2.9%
Q1 2025May 8, 2025 · After close−2.6%
Q4 2024Feb 26, 2025−3.1%
Q3 2024Nov 12, 2024 · After close−8.7%
Q2 2024Aug 12, 2024 · After close+0.5%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · After close0.0%
Q4 2023Mar 29, 2024 · After close−4.9%
Q3 2023Nov 13, 2023 · Before open+1.4%
Q2 2023Aug 11, 2023 · After close+0.6%
Q1 2023May 12, 2023 · After close−3.3%
Q4 2022Mar 27, 2023 · Before open+1.6%
Q3 2022Nov 9, 2022 · After close−4.7%
Q2 2022Aug 12, 2022 · After close−4.5%
Q1 2022May 13, 2022 · After close+1.9%
Q4 2021Mar 28, 2022 · After close+11.3%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck34 slidesSeptember 2026
Investor Presentation (August 2026)Investor deck31 slidesAugust 2026
Investor Presentation (May 2026)Investor deck50 slidesMay 2026
Investor Presentation (March 2026)Investor deck48 slidesMarch 2026
Technical Presentation (February 2026)Technical17 slidesFeb 6, 2026
Investor Presentation (January 2026)Investor deck48 slidesJanuary 2026
ASH 2025 Oral PresentationConference14 slidesDec 7, 2025
Investor Presentation (December 2025)Investor deck41 slidesDecember 2025
Investor Presentation (November 2025)Investor deck40 slidesNovember 2025
Investor Presentation (September 2025)Investor deck54 slidesSeptember 2025
All 25 decks
DeckKindSlidesDate
Investor Presentation (August 2025)Investor deck54 slidesAugust 2025
Investor Presentation (July 2025)Investor deck54 slidesJuly 2025
ASCO 2025Conference13 slidesJun 3, 2025
ASCO 2025Conference13 slidesJun 3, 2025
Investor Presentation (June 2025)Investor deck54 slidesJune 2025
Investor Presentation (May 2025)Investor deck57 slidesMay 2025
Investor Presentation (April 2025)Investor deck58 slidesApril 2025
Investor Presentation (March 2025)Investor deck61 slidesMarch 2025
Investor Presentation (February 2025)Investor deck61 slidesFebruary 2025
66th American Society of Hematology (ASH) Annual Meeting and Exposition 2024Conference17 slidesDec 10, 2024
Investor Presentation (October 2024)Investor deck48 slidesOctober 2024
Investor Presentation (August 2024)Investor deck40 slidesAugust 2024
Investor Presentation (July 2024)Investor deck40 slidesJuly 2024
ASGCT 2023Conference25 slidesMay 2023
Investor Presentation (December 2022)Investor deck17 slidesDec 16, 2022

Open Decks

Financings

RaiseDate
Public offering of common stock
Announced: US$125M · US$11 a share · J.P. Morgan
Dealers: J.P. Morgan (lead)
Buyers: Eventide Asset Management; Janus Henderson Investors; Ridgeback Capital Investments L.P.; Wellington Management
Use of proceeds: Fund NXC-201 development, working capital and general corporate purposes
Sep 29, 2026
Public offering of common stock and pre-funded warrants
Announced: US$100M · US$5.1 a share · Morgan Stanley +2
Dealers: Morgan Stanley (lead), Citizens Capital Markets, Mizuho
Use of proceeds: Fund NXC-201 development, working capital and general corporate purposes
Dec 7, 2025
Strategic investment of strategic investment
Closed: strategic investment
Buyers: Goose Capital; Dr. Nancy T. Chang
Sep 8, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$5.00 a share on Dec 15, 2021.

Price
US$5.00 a share
Shares offered
4,200,000 shares of common stock
Offering size
US$21 million
Underwriters' option
Up to 630,000 more shares
Listing
IMMX on the Nasdaq Capital Market
Underwriter
ThinkEquity
Shares delivered
On or about Dec 20, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceJul 20, 2021
Filed publiclySep 17, 2021
Amended 4 timesNewest Nov 4, 2021
Shares registered with an exchangeDec 13, 2021
Declared effective by the SECDec 15, 2021
Final prospectus, with the priceDec 17, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Dec 17, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue000-89.5M000
Cost of revenue364.5K115.4K5.47K2.13K2.47K2.32K1.08K
Gross profit-364.5K-115.4K-5.47K-89.5M-2.47K-2.32K-1.08K
Research and development16.3M11.3M8.74M4.20M126.5K248.1K583.2K
Selling, general and administrative13.7M11.4M7.41M4.02M1.23M205.7K259.3K
Operating income-30.0M-22.7M-16.1M-8.22M-1.35M-453.9K-842.5K
Depreciation and amortization245.7K32.9K5.47K2.13K2.47K2.32K1.08K
EBITDA-29.7M-22.6M-16.1M-8.22M-1.35M-451.5K-841.4K
Interest expense0497179.9K102.0K110.0K
Income before tax-29.4M-21.7M-15.6M-8.22M-24.4M-1.13M-952.3K
Income tax37.7K41.0K26.4K10.3K6.01K17.5K20.6K
Net income-29.4M-21.6M-15.4M-8.23M-24.4M-1.15M-972.8K
Earnings per share, basic-0.89-0.76-0.89-0.59-6.64-0.34-0.29
Earnings per share, diluted-0.89-0.76-0.89-0.59-6.64-0.34

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents93.9M17.7M17.5M13.4M17.6M391.1K734.0K
Short-term investments6.48M0
Receivables1.97M1.17M255.7K25.7K127.4K175.7K
Current assets101.2M20.2M19.8M14.9M18.2M532.2K933.3K
Property, plant and equipment2.52M1.74M50.2K3.56K5.70K7.36K9.68K
Total assets104.8M22.9M19.9M14.9M18.2M539.6K942.9K
Accounts payable5.44M5.39M1.43M143.1K142.9K252.3K247.5K
Current liabilities10.1M8.69M3.72M1.27M202.0K5.27M4.59M
Total debt1.07M1.07M50.0K4.10M4.10M
Total liabilities11.0M9.70M3.72M1.75M202.0K5.27M4.59M
Shareholders' equity93.8M13.3M16.4M13.2M18.0M-4.73M-3.65M
Shares outstanding53.0M27.5M19.9M13.9M13.2M3.38M3.38M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-23.9M-14.6M-11.4M-7.41M-1.59M-404.7K-790.0K
Capital spending-732.9K-1.18M-52.1K-3-802-4-7.31K
Free cash flow-24.7M-15.8M-11.4M-7.41M-1.59M-404.7K-797.3K
Cash from investing-7.21M-1.18M-52.1K-802-802-7.31K
Cash from financing107.4M15.9M15.5M3.23M18.8M18.8M1.05M
Share buybacks-44.0K-100.0K0
Change in cash76.2M172.2K4.07M-4.21M17.3M-342.9K271.7K

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 20, 2026Insider tradeSEC
4 · Change in ownershipNov 20, 2026Insider tradeSEC
8-K · Current reportNov 12, 2026ResultsSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeOct 27, 2026Big-stake noticeSEC
8-K · Current reportSep 30, 2026Current reportSEC
FWP · Free writing prospectusSep 29, 2026Offer documentSEC
424B5 · ProspectusSep 29, 2026Offer documentSEC
8-K · Current reportSep 29, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeAug 14, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 7, 2026Quarterly reportSEC
8-K · Current reportJul 20, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJun 5, 2026Big-stake noticeSEC
8-K · Current reportMay 29, 2026Meeting outcomeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
4 · Change in ownershipMay 29, 2026Insider tradeSEC
8-K · Current reportMay 21, 2026Current reportSEC
424B5 · ProspectusMay 21, 2026Offer documentSEC
FWP · Free writing prospectusMay 21, 2026Offer documentSEC
8-K · Current reportMay 21, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 4, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersApr 6, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 6, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 6, 2026Meeting noticeSEC
8-K · Current reportMar 30, 2026Current reportSEC
10-K/A · Annual report, amendedMar 27, 2026Annual reportSEC
S-8 · Registration statement for employee plansMar 25, 2026Offer documentSEC
8-K · Current reportMar 25, 2026Material contractSEC
424B5 · ProspectusMar 25, 2026Offer documentSEC
10-K · Annual reportMar 25, 2026Annual reportSEC
SCHEDULE 13G · Big-stake noticeMar 20, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveJan 23, 2026Other filingsSEC
CORRESP · Letter to the SECJan 16, 2026Other filingsSEC
UPLOAD · Letter from the SECJan 16, 2026Other filingsSEC
S-3 · Registration statementJan 9, 2026Offer documentSEC
4 · Change in ownershipDec 11, 2025Insider tradeSEC
4 · Change in ownershipDec 10, 2025Insider tradeSEC
4 · Change in ownershipDec 10, 2025Insider tradeSEC
8-K · Current reportDec 8, 2025Material contractSEC
424B5 · ProspectusDec 8, 2025Offer documentSEC
8-K · Current reportDec 8, 2025Current reportSEC
FWP · Free writing prospectusDec 8, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveDec 2, 2025Other filingsSEC
CORRESP · Letter to the SECNov 26, 2025Other filingsSEC
8-K · Current reportNov 26, 2025Current reportSEC
10-Q · Quarterly reportNov 7, 2025Quarterly reportSEC
S-3 · Registration statementOct 6, 2025Offer documentSEC
4 · Change in ownershipSep 17, 2025Insider tradeSEC
4 · Change in ownershipSep 17, 2025Insider tradeSEC
3 · Initial statement of ownershipSep 17, 2025Insider tradeSEC
8-K · Current reportSep 8, 2025Material contractSEC
10-Q · Quarterly reportAug 8, 2025Quarterly reportSEC
8-K · Current reportJun 23, 2025Meeting outcomeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 23, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
424B5 · ProspectusJun 3, 2025Offer documentSEC
8-K · Current reportJun 3, 2025Material contractSEC
ARS · Annual report to shareholdersMay 19, 2025Annual reportSEC
10-Q/A · Quarterly report, amendedMay 19, 2025Quarterly reportSEC
DEFA14A · Additional proxy materialMay 19, 2025Meeting noticeSEC
10-K/A · Annual report, amendedMay 19, 2025Annual reportSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
DEFA14A · Additional proxy materialMay 2, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2025Meeting noticeSEC
10-K · Annual reportMar 24, 2025Annual reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 29, 2025Big-stake noticeSEC
4 · Change in ownershipDec 26, 2024Insider tradeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
4 · Change in ownershipAug 26, 2024Insider tradeSEC
4 · Change in ownershipAug 19, 2024Insider tradeSEC
10-Q · Quarterly reportAug 12, 2024Quarterly reportSEC
4 · Change in ownershipJul 31, 2024Insider tradeSEC
8-K · Current reportJul 26, 2024Current reportSEC
8-K · Current reportJul 19, 2024Current reportSEC
S-8 · Registration statement for employee plansJul 19, 2024Offer documentSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
8-K · Current reportJun 14, 2024Management or board changeSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
4 · Change in ownershipJun 5, 2024Insider tradeSEC
4 · Change in ownershipJun 5, 2024Insider tradeSEC
DEFA14A · Additional proxy materialMay 21, 2024Meeting noticeSEC
8-K · Current reportMay 20, 2024FinancingSEC
DMay 20, 2024Other filingsSEC
4 · Change in ownershipMay 20, 2024Insider tradeSEC
4 · Change in ownershipMay 20, 2024Insider tradeSEC
4 · Change in ownershipMay 20, 2024Insider tradeSEC
4 · Change in ownershipMay 20, 2024Insider tradeSEC
4 · Change in ownershipMay 20, 2024Insider tradeSEC
4 · Change in ownershipMay 20, 2024Insider tradeSEC
4 · Change in ownershipMay 20, 2024Insider tradeSEC
4 · Change in ownershipMay 14, 2024Insider tradeSEC
4 · Change in ownershipMay 14, 2024Insider tradeSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
ARS · Annual report to shareholdersApr 29, 2024Annual reportSEC
DEF 14A · Proxy statementApr 29, 2024Meeting noticeSEC
10-K · Annual reportMar 29, 2024Annual reportSEC
S-8 · Registration statement for employee plansFeb 16, 2024Offer documentSEC
424B5 · ProspectusFeb 7, 2024Offer documentSEC
SC 13G · Big-stake noticeFeb 7, 2024Big-stake noticeSEC
8-K · Current reportFeb 6, 2024Material contractSEC
424B5 · ProspectusFeb 5, 2024Offer documentSEC
8-K · Current reportFeb 5, 2024Current reportSEC
4 · Change in ownershipDec 12, 2023Insider tradeSEC
10-Q · Quarterly reportNov 9, 2023Quarterly reportSEC
4/A · Change in ownership, amendedNov 9, 2023Insider tradeSEC
4/A · Change in ownership, amendedNov 9, 2023Insider tradeSEC
EFFECT · Notice that a registration is effectiveSep 29, 2023Other filingsSEC
CORRESP · Letter to the SECSep 26, 2023Other filingsSEC
UPLOAD · Letter from the SECSep 26, 2023Other filingsSEC
S-3 · Registration statementSep 25, 2023Offer documentSEC
4 · Change in ownershipSep 18, 2023Insider tradeSEC
4 · Change in ownershipSep 15, 2023Insider tradeSEC
4 · Change in ownershipSep 14, 2023Insider tradeSEC
4 · Change in ownershipSep 12, 2023Insider tradeSEC
4 · Change in ownershipSep 11, 2023Insider tradeSEC
4 · Change in ownershipSep 8, 2023Insider tradeSEC
4 · Change in ownershipSep 6, 2023Insider tradeSEC
4 · Change in ownershipSep 5, 2023Insider tradeSEC
SC 13D · Big-stake noticeAug 30, 2023Big-stake noticeSEC
4 · Change in ownershipAug 23, 2023Insider tradeSEC
3 · Initial statement of ownershipAug 23, 2023Insider tradeSEC
8-K · Current reportAug 22, 2023Material contractSEC
4 · Change in ownershipAug 14, 2023Insider tradeSEC
4 · Change in ownershipAug 14, 2023Insider tradeSEC
4 · Change in ownershipAug 14, 2023Insider tradeSEC
4 · Change in ownershipAug 14, 2023Insider tradeSEC
4 · Change in ownershipAug 14, 2023Insider tradeSEC
4 · Change in ownershipAug 14, 2023Insider tradeSEC
4 · Change in ownershipAug 14, 2023Insider tradeSEC
10-Q · Quarterly reportAug 11, 2023Quarterly reportSEC
424B5 · ProspectusJul 14, 2023Offer documentSEC
8-K · Current reportJul 14, 2023Material contractSEC
S-8 · Registration statement for employee plansJun 13, 2023Offer documentSEC
8-K · Current reportJun 8, 2023Meeting outcomeSEC
10-Q · Quarterly reportMay 12, 2023Quarterly reportSEC
DEFA14A · Additional proxy materialApr 25, 2023Meeting noticeSEC
ARS · Annual report to shareholdersApr 25, 2023Annual reportSEC
DEF 14A · Proxy statementApr 25, 2023Meeting noticeSEC
10-K · Annual reportMar 27, 2023Annual reportSEC
424B5 · ProspectusMar 22, 2023Offer documentSEC
8-K · Current reportMar 22, 2023Material contractSEC
8-K/A · Current report, amendedMar 13, 2023Current reportSEC
8-K · Current reportMar 10, 2023Material contractSEC
8-K · Current reportJan 18, 2023Material contractSEC
EFFECT · Notice that a registration is effectiveJan 12, 2023Other filingsSEC
CORRESP · Letter to the SECJan 9, 2023Other filingsSEC
UPLOAD · Letter from the SECJan 6, 2023Other filingsSEC
S-3 · Registration statementJan 3, 2023Offer documentSEC
8-K · Current reportDec 16, 2022Current reportSEC
8-K · Current reportDec 14, 2022Material contractSEC
4 · Change in ownershipNov 15, 2022Insider tradeSEC
4 · Change in ownershipNov 15, 2022Insider tradeSEC
10-Q · Quarterly reportNov 9, 2022Quarterly reportSEC
10-Q · Quarterly reportAug 12, 2022Quarterly reportSEC
4/A · Change in ownership, amendedJul 22, 2022Insider tradeSEC
RW · Request to withdraw a registrationJul 18, 2022Other filingsSEC
4 · Change in ownershipJul 18, 2022Insider tradeSEC
4 · Change in ownershipJul 18, 2022Insider tradeSEC
4 · Change in ownershipJul 18, 2022Insider tradeSEC
4 · Change in ownershipJul 18, 2022Insider tradeSEC
4 · Change in ownershipJul 18, 2022Insider tradeSEC
4 · Change in ownershipJul 18, 2022Insider tradeSEC
4 · Change in ownershipJul 18, 2022Insider tradeSEC
4 · Change in ownershipJul 18, 2022Insider tradeSEC
RW WDJun 30, 2022Other filingsSEC
8-K · Current reportJun 9, 2022Meeting outcomeSEC
FWP · Free writing prospectusMay 27, 2022Offer documentSEC
S-1 · Registration statementMay 27, 2022Offer documentSEC
DRS · Draft registration statementMay 23, 2022Offer documentSEC
10-Q · Quarterly reportMay 13, 2022Quarterly reportSEC
DEFA14A · Additional proxy materialApr 25, 2022Meeting noticeSEC
DEF 14A · Proxy statementApr 25, 2022Meeting noticeSEC

This page holds 200 of 248 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Immix Biopharma, Inc.’s releases · as of Sep 29, 2026

Common shares
82,902,951
Fully diluted
82,902,951

Fully diluted

LineShares
Common shares82,902,951

Share count over time

CountShares
Nov 22, 202682,902,951

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Janus Henderson12.1M14.4%US$126MSep 30, 2026
Eventide Asset Management, LLC5.19M6.2%US$54MSep 30, 2026
Saturn V Capital Management LP4.66M5.6%US$48.5MSep 30, 2026
BlackRock4.54M5.4%US$47.2MSep 30, 2026
Vanguard4.1M4.9%US$42.6MSep 30, 2026
State Street3.3M3.9%US$34.4MSep 30, 2026
Opaleye Management Inc.2.83M3.4%US$29.4MSep 30, 2026
Balyasny Asset Management L.P.2.64M3.2%US$27.5MSep 30, 2026
Ameriprise1.86M2.2%US$19.4MSep 30, 2026
Marshall Wace, LLP1.85M2.2%US$19.3MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Franklin Templeton1.79M2.1%US$14.2MSep 30, 2026
T. Rowe Price1.75M2.1%US$18.2MSep 30, 2026
Wellington1.65M2.0%US$17.2MSep 30, 2026
Geode Capital1.44M1.7%US$15MSep 30, 2026
AllianceBernstein1.32M1.6%US$13.8MSep 30, 2026
Velan Capital Investment Management LP1.08M1.3%US$11.3MSep 30, 2026
Bleichroeder LP1M1.2%US$10.4MSep 30, 2026
Citadel931K1.1%US$9.69MSep 30, 2026
Millennium866K1.0%US$9.01MSep 30, 2026
abrdn819K0.98%US$8.52MSep 30, 2026
Adage Capital Partners Gp, L.L.C.727K0.87%US$7.57MSep 30, 2026
Blue Owl Capital Holdings LP602K0.72%US$6.26MSep 30, 2026
Northern Trust521K0.62%US$5.42MSep 30, 2026
LGT Fund Management Co Ltd.461K0.55%US$4.8MSep 30, 2026
Alyeska Investment Group, L.P.455K0.54%US$4.73MSep 30, 2026
Monashee Investment Management LLC450K0.54%US$4.68MSep 30, 2026
Bank of America429K0.51%US$4.47MSep 30, 2026
Sphera Funds Management LTD.356K0.42%US$3.7MSep 30, 2026
Institute for Wealth Management, LLC.340K0.41%US$3.54MSep 30, 2026
Picton Mahoney Asset Management333K0.40%US$3.47MSep 30, 2026
Longaeva Partners L.P.318K0.38%US$3.31MSep 30, 2026
Qube Research & Technologies Ltd310K0.37%US$3.22MSep 30, 2026
Morgan Stanley293K0.35%US$3.05MSep 30, 2026
BNY288K0.34%US$3MSep 30, 2026
Invesco279K0.33%US$2.9MSep 30, 2026
Seven Grand Managers, LLC260K0.31%US$2.7MSep 30, 2026
Informed Momentum Co LLC239K0.29%US$2.49MSep 30, 2026
KVP Capital Advisors, LP230K0.27%US$2.4MSep 30, 2026
TD214K0.26%US$2.26MSep 30, 2026
D. E. Shaw & Co., Inc.208K0.25%US$2.16MSep 30, 2026
Schwab192K0.23%US$2MSep 30, 2026
UBS187K0.22%US$1.94MSep 30, 2026
Goldman Sachs131K0.16%US$1.36MSep 30, 2026
Manufacturers Life Insurance Company, The128K0.15%US$1.33MSep 30, 2026
Nuveen125K0.15%US$1.3MSep 30, 2026
Rafferty Asset Management, LLC89,3030.11%US$929KSep 30, 2026
Moore Capital Management, LP89,0690.11%US$927KSep 30, 2026
Tocqueville Asset Management L.P.87,3500.10%US$909KSep 30, 2026
Bridgeway Capital Management, LLC80,0000.10%US$832KSep 30, 2026
Maven Securities LTD76,0000.09%US$791KSep 30, 2026

This page holds 50 of 133 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Eventide Healthcare & Life Sciences Fund3.89M4.6%US$40.1MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF2.1M2.5%US$21.7MJun 30, 2026
Vanguard Total Stock Market Index Fund1.78M2.1%US$18.4MJun 30, 2026
T. Rowe Price Health Sciences Fund, Inc.1.33M1.6%US$13.7MJun 30, 2026
iShares Russell 2000 ETF1.07M1.3%US$11MJun 30, 2026
Vanguard Extended Market Index Fund681K0.81%US$7.03MJun 30, 2026
Columbia Small Cap Value Discovery Fund484K0.58%US$4.02MJul 31, 2026
Fidelity Small Cap Index Fund449K0.54%US$3.74MJul 31, 2026
iShares Russell 2000 Growth ETF371K0.44%US$3.82MJun 30, 2026
Franklin Biotechnology Discovery Fund357K0.43%US$2.97MJul 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Fidelity Extended Market Index Fund299K0.36%US$2.69MMay 31, 2026
Timber Point Global Allocations Fund140K0.17%US$1.44MJun 30, 2026
iShares Micro-Cap ETF138K0.16%US$1.42MJun 30, 2026
Fidelity Total Market Index Fund109K0.13%US$985KMay 31, 2026
Schwab Small-Cap Index Fund99,7940.12%US$830KJul 31, 2026
Fidelity Series Total Market Index Fund88,3360.11%US$795KMay 31, 2026
T. Rowe Price Health Sciences Portfolio82,6130.10%US$852KJun 30, 2026
Ultra-Small Company Fund80,0000.10%US$825KJun 30, 2026
Master Small Cap Index Series76,7860.09%US$792KJun 30, 2026
Direxion Daily S&P Biotech Bull 3X Shares71,4950.09%US$595KJul 31, 2026
Nuveen Small Cap Blend Index Fund54,6090.07%US$454KJul 31, 2026
Schwab Total Stock Market Index Fund47,3800.06%US$394KJul 31, 2026
EQ/2000 Managed Volatility Portfolio44,7230.05%US$461KJun 30, 2026
Fidelity Small Cap Growth Index Fund38,4840.05%US$397KJun 30, 2026
Virtus Biotech Clinical Trials Etf36,7820.04%US$306KJul 31, 2026
Nuveen Equity Index Fund36,0340.04%US$300KJul 31, 2026
Blackstone Alternative Multi-Strategy Fund33,5340.04%US$346KJun 30, 2026
Columbia Variable Portfolio - Small Company Growth Fund30,3900.04%US$313KJun 30, 2026
LVIP State Street Small-Cap Index Fund29,8000.04%US$307KJun 30, 2026
Health Sciences Trust27,9920.03%US$289KJun 30, 2026
Fidelity Nasdaq Composite Index Fund22,9330.03%US$206KMay 31, 2026
Vanguard Institutional Total Stock Market Index Fund22,8350.03%US$235KJun 30, 2026
Vanguard Balanced Index Fund22,5850.03%US$233KJun 30, 2026
Small Cap Index Fund21,1240.03%US$218KJun 30, 2026
Biotechnology Ultrasector Profund20,0620.02%US$167KJul 31, 2026
EQ/T.Rowe Price Health Sciences Portfolio19,7040.02%US$203KJun 30, 2026
Global X Russell 2000 ETF19,5400.02%US$163KJul 31, 2026
EQ/AB Small Cap Growth Portfolio16,7800.02%US$173KJun 30, 2026
EQ/Small Company Index Portfolio16,7800.02%US$173KJun 30, 2026
ATM Small Cap Managed Volatility Portfolio14,9020.02%US$154KJun 30, 2026
Small Cap Core Fund14,3960.02%US$148KJun 30, 2026
State Street Small/Mid Cap Equity Index Portfolio14,3000.02%US$147KJun 30, 2026
MetLife Russell 2000 Index Portfolio14,1310.02%US$146KJun 30, 2026
Small-Cap Index Portfolio11,7900.01%US$122KJun 30, 2026
Multi-Manager U.S. Small Cap Equity Fund10,6220.01%US$94,854Apr 30, 2026
Profund Vp Biotechnology9,3290.01%US$96,182Jun 30, 2026
1290 VT Micro Cap Portfolio9,2030.01%US$94,883Jun 30, 2026
NVIT Small Cap Index Fund9,1660.01%US$94,501Jun 30, 2026
Avantis U.S. Small Cap Equity ETF8,6920.01%US$78,228May 31, 2026
Small Cap Index Trust8,5230.01%US$87,872Jun 30, 2026

This page holds 50 of 82 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Morris Gabriel S
Director, Officer: CFO, President
Buy1,418USD 7.06US$10,011Nov 18, 2026
Rachman Ilya M
Director, Officer: CEO, Chairman
Buy1,408USD 7.10US$10,000Nov 18, 2026

Big stakes

StakeStakeSharesDateFiling
Janus Henderson Group PLC14.00%9.78MJun 30, 2026Schedule 13G
Saturn V Capital Management LP6.97%3.69MDec 26, 2025Schedule 13G
Eventide Asset Management, LLC5.60%3.89MJun 30, 2026Schedule 13G
BlackRock, Inc.5.50%4.54MSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Nancy Chang
Other companies: Galera Therapeutics, Inc. (Director · Since at least Dec 30, 2024); W&T Offshore, Inc. (Director · Since at least Apr 28, 2023); MoonLake Immunotherapeutics (Director · Oct 19, 2020 – Oct 19, 2020 · Past); SciClone Pharmaceuticals Inc (Director · Sep 17, 2013 – Oct 13, 2017 · Past); Charles River Laboratories International, Inc. (Director · Oct 24, 2007 – May 7, 2010 · Past); Tanox Inc (Director · Dec 31, 2005 – Nov 2, 2006 · Past)
Independent Director · Since at least Sep 8, 2025
Magda Marquet
Other companies: First Tracks Biotherapeutics, Inc. (Director · Since at least Jun 15, 2026)
Director · Since at least May 22, 2026
Carey NgIndependent Director · Since at least Dec 15, 2021
David HeHead of Technical Operations · Since at least Nov 4, 2026
David MarksChief Medical Officer · Since at least Nov 5, 2026
Gabriel MorrisPresident and Chief Financial Officer · Since at least Jul 14, 2022
Graham RossCMO & Head of Clinical Dev. · Dec 15, 2021 – Dec 15, 2021 · Past
Helen AdamsDirector · Since at least May 15, 2024
Ilya RachmanChief Executive and Scientific Officer · Since at least Dec 15, 2021
Jane BuchanDirector · Since at least May 22, 2026
All 14 people
PersonSeat
Jason HsuIndependent Director · Since at least Dec 15, 2021
Michael GrabowChief Commercial Officer · Since at least Nov 12, 2025
Vladimir P TorchilinScientific Co-Founder · Dec 15, 2021 – Dec 20, 2021 · Past
Yekaterina ChudnovskyDirector · Since at least May 22, 2026

Open People

Log in to ask 6ix AI your own questions about Immix Biopharma, Inc.